{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:37:56Z","timestamp":1777779476320,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12473"],"award-info":[{"award-number":["12473"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2020-2023"],"award-info":[{"award-number":["2020-2023"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clinthera.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T20:48:44Z","timestamp":1753735724000},"page":"894-903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Access to EU-Authorized Nonreimbursed Anticancer Medicines: An Explorative Survey Among Dutch Medical Oncologists"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0701-1209","authenticated-orcid":false,"given":"H. Colinda","family":"Post","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte H. C\uff0e","family":"Bomhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla E. M\uff0e","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke W. M\uff0e","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Schutte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline M\uff0e","family":"Bunnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.07.003_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0002","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S1470-2045(23)00592-2","article-title":"Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications","volume":"25","author":"Koole","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0003","unstructured":"[DUTCH] Zorginstituut Nederland - missie en visie. Accessed October 7, 2024. https:\/\/www.zorginstituutnederland.nl\/over-ons\/organisatie\/missie-en-visie."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0004","unstructured":"Government D. Geneesmiddel Trodelvy niet in basispakket (in Dutch). Accessed October 7, 2024. https:\/\/www.rijksoverheid.nl\/actueel\/nieuws\/2023\/03\/28\/geneesmiddel-trodelvy-niet-in-basispakket2023\/03\/28."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0005","first-page":"8","article-title":"[in Dutch] Sluis voor dure ziekenhuisgeneesmiddelen werkt","author":"Leijen","year":"2023","journal-title":"Zorginstituut Magazine"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0006","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/cancers12082313","article-title":"Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe","volume":"12","author":"Uyl-de Groot","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101208","article-title":"Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries","volume":"8","author":"Post","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0008","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jval.2018.01.003","article-title":"Time to entry for new cancer medicines: from European Union-wide marketing authorization to patient access in Belgium, Estonia, Scotland, and Sweden","volume":"21","author":"Ferrario","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0009","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1186\/s12913-023-10421-x","article-title":"Uptake and availability of new outpatient cancer medicines in 2010-2021 in Nordic countries - survey of competent authorities","volume":"23","author":"Sarnola","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0010","series-title":"DUTCH] Wachttijd dure medicijnen loopt op tot bijna 600 dagen","author":"Vaessen","year":"2023"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0011","author":"Kuipers"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0012","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(21)00707-5","article-title":"Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform","volume":"23","author":"Zeverijn","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0013","unstructured":"[in Dutch] Over de commissie DAP (Drug Access Protocol) - Accessed October 7, 2024. https:\/\/www.nvmo.org\/bestuur-en-commissies\/commissie-dap\/over-de-commissie-dap\/2023."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0014","unstructured":"DRUG Access Protocol - participating centers and drugs. Accessed October 7, 2024. https:\/\/drupstudy.nl\/wp-content\/uploads\/2023\/04\/DAP-deelnemende-centra-per-middel_april_2023.pdf2023."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0015","article-title":"Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol","volume":"39","author":"Verkerk","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0016","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/23294515.2022.2110963","article-title":"Physicians' Perspectives on ethical issues regarding expensive anti-cancer treatments: a qualitative study","volume":"13","author":"Bomhof","year":"2022","journal-title":"AJOB Empir Bioeth"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2023.104865","article-title":"Systemic anticancer treatment in the Netherlands: few hospitals treat many patients, many hospitals treat few patients","volume":"135","author":"Peeters","year":"2023","journal-title":"Health Policy"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0018","unstructured":"Government F Haute autorit\u00e9 de sant\u00e9 - GUIDE autorisation d\u2019acc\u00e8s pr\u00e9coce aux m\u00e9dicaments: doctrine d\u2019\u00e9valuation de la HAS. Accessed October 7, 2024. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/acces_precoces_-_doctrine.pdf2022."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0019","unstructured":"Team\" NECDF. Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund) - a new deal for patients, taxpayers and industry. Accessed October 7, 2024. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2024\/04\/appraisal-and-funding-of-cancer-drugs-from-July-2016.pdf2016."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41571-021-00584-z","article-title":"The value of anticancer drugs - a regulatory view","volume":"19","author":"Pignatti","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0021","article-title":"Should new health technology be available only for patients able and willing to pay?","volume":"5","author":"Calcoen","year":"2017","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0022","unstructured":"The benefit assessment of medicinal products in accordance with the German Social Code, Book Five (SGB V), section 35a - Act on the Reform of the Market for Medicinal Products (AMNOG). Accessed October 7, 2024. https:\/\/www.g-ba.de\/english\/benefitassessment\/: German Government (Gemeinsamer Bundesausschuss)."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0023","series-title":"Principles of Biomedical Ethics","author":"Beauchamp","year":"2019"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0024","unstructured":"WMA International Code of Medical Ethics \u2013 WMA \u2013 The World Medical Association. Accessed October 7, 2024. https:\/\/www.wma.net\/policies-post\/wma-international-code-of-medical-ethics\/."},{"key":"10.1016\/j.clinthera.2025.07.003_bib0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JOP.2012.000680","article-title":"Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges","volume":"9","author":"Han","year":"2013","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062104","article-title":"Patients' and oncologists' perceptions towards the discussion on high-cost innovative cancer therapies: findings from a qualitative study","volume":"12","author":"Bashkin","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0027","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdj136","article-title":"Do oncologists discuss expensive anti-cancer drugs with their patients?","volume":"17","author":"Thomson","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0028","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.3390\/curroncol28060400","article-title":"Current attitudes toward unfunded cancer therapies among Canadian medical oncologists","volume":"28","author":"Wong","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1258\/shorts.2011.011050","article-title":"The views of patients and the general public about expensive anti-cancer drugs in the NHS: a questionnaire-based study","volume":"2","author":"Jenkins","year":"2011","journal-title":"JRSM Short Rep"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0030","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1200\/JCO.2009.22.7793","article-title":"To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option","volume":"27","author":"Mileshkin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0031","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/annonc\/mdq068","article-title":"Communication about high-cost drugs in oncology\u2013the patient view","volume":"21","author":"Kaser","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0032","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(02)00877-X","article-title":"Informing and involving cancer patients in their own care","volume":"3","author":"Jefford","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000170","article-title":"Discussing and prescribing expensive unfunded anticancer drugs in Australia","volume":"2","author":"Karikios","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0034","article-title":"Ethics of access to newly approved expensive medical treatments: multi-stakeholder dialogues in a publicly funded healthcare system","volume":"14","author":"Bomhof","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0035","series-title":"National survey on access to new oncology drugs pending health technology assessment and financial arrangements (e13599)","year":"2021"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2024.100490","article-title":"The narrow road to expanded access","volume":"41","author":"Post","year":"2024","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0037","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1111\/bcp.15094","article-title":"Free-of-charge medicine schemes in the NHS: a local and regional drug and therapeutic committee's experience","volume":"88","author":"O'Callaghan","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.07.003_bib0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12874-015-0016-z","article-title":"Exploring physician specialist response rates to web-based surveys","volume":"15","author":"Cunningham","year":"2015","journal-title":"BMC Med Res Methodol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:22:33Z","timestamp":1777490553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0149291825002401"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to EU-Authorized Nonreimbursed Anticancer Medicines: An Explorative Survey Among Dutch Medical Oncologists","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}